Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

235
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
235
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

587
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
587
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

43
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
43
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

58
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
58
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

89
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
89
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

67
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
67

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA.

Translational psychiatry·2026
Same author

Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial.

The Lancet. Infectious diseases·2026
Same author

PET imaging of FAAH in chronic Cannabis users: longitudinal assessment during short-term abstinence.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Longitudinal neurocognitive trajectories in a large cohort of youth who use cannabis: combining self-report and toxicology.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

A framework for scholarly development in health professions education.

Academic medicine : journal of the Association of American Medical Colleges·2026
Same author

Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Related Experiment Video

Updated: Jun 6, 2025

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
07:41

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Published on: June 5, 2017

9.9K

MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis.

Marilyn A Huestis1, William B Smith2, Cathrine Leonowens3

  • 1Institute of Emerging Health Professions, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

CPT: Pharmacometrics & Systems Pharmacology
|November 26, 2024
PubMed
Summary

Midomafetamine (MDMA) pharmacokinetics are not significantly affected by food. MDMA is a strong CYP2D6 inhibitor, but unlikely to impact drugs sensitive to renal transporters.

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

7.8K
Author Spotlight: Advancing Cell Membrane Biophysics - Exploring Interactions and Challenges Through Experimental and Computational Approaches
07:31

Author Spotlight: Advancing Cell Membrane Biophysics - Exploring Interactions and Challenges Through Experimental and Computational Approaches

Published on: September 1, 2023

2.1K

Related Experiment Videos

Last Updated: Jun 6, 2025

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
07:41

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Published on: June 5, 2017

9.9K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

7.8K
Author Spotlight: Advancing Cell Membrane Biophysics - Exploring Interactions and Challenges Through Experimental and Computational Approaches
07:31

Author Spotlight: Advancing Cell Membrane Biophysics - Exploring Interactions and Challenges Through Experimental and Computational Approaches

Published on: September 1, 2023

2.1K

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Clinical Pharmacology

Background:

  • Midomafetamine (MDMA) is under FDA review for PTSD treatment.
  • MDMA is metabolized by CYP2D6 and inhibits CYP2D6, MATE1, OCT1, and OCT2.
  • Understanding MDMA pharmacokinetics is crucial for safe and effective clinical use.

Purpose of the Study:

  • To evaluate the effect of food on MDMA pharmacokinetics.
  • To develop and verify population pharmacokinetic (PopPK) and physiologically based pharmacokinetic (PBPK) models for MDMA.
  • To predict drug-drug interactions (DDIs) and pharmacokinetics for clinical dosing regimens.

Main Methods:

  • A pharmacokinetic phase I study assessed food effects.
  • PopPK and PBPK models were developed and verified using study data, published data, and in vitro data.
  • PBPK simulations investigated food effects, dosing regimens, and DDIs.

Main Results:

  • A high-fat meal did not alter MDMA plasma concentrations but delayed Tmax.
  • PopPK analysis found no clinically significant covariates.
  • PBPK models predicted minor exposure differences for single vs. split doses, with delayed Tmax for split doses.
  • MDMA is a potent CYP2D6 inhibitor, with minimal predicted impact on renal transporter substrates.

Conclusions:

  • Food does not significantly alter MDMA pharmacokinetics.
  • MDMA's pharmacokinetic profile is predictable across clinical doses.
  • MDMA is a strong CYP2D6 inhibitor, but unlikely to cause clinically relevant DDIs via renal transporters.